{"id":404268,"date":"2020-12-22T07:03:31","date_gmt":"2020-12-22T12:03:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=404268"},"modified":"2020-12-22T07:03:31","modified_gmt":"2020-12-22T12:03:31","slug":"quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/","title":{"rendered":"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01 <\/strong>\n      <\/p>\n<p align=\"justify\">NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx Group Limited (\u201cQuantuMDx\u201d), a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new strain of SARS-CoV-2.<\/p>\n<p align=\"justify\">The UK COVID Genomics Consortium and Public Health England have identified a new strain of SARS-CoV-2 which is characterised by multiple spike gene variants. The new strain known as VUI-202012\/01 or lineage B.1.1.7 appears to be significantly more transmissible than other circulating linages and there are reports that some diagnostic tests may be affected. <\/p>\n<p align=\"justify\">QuantuMDx continually monitors genomic sequences deposited to the NCBI and GISAID databases as part of post market surveillance. Analysis of VUI-202012\/01 genomes shows that none of the variants interfere with QuantuMDx\u2019s three target QMDx SARS-CoV-2 test.\u00a0 <\/p>\n<p align=\"justify\">The high performance QuantuMDx SARS-CoV-2 assay has been proven against seven separate sample cohorts including independent evaluations from FIND, several hospitals and UK Department of Health and Social Care. Aggregated across cohorts, totalling over 800 samples, clinical sensitivity was shown to be 98.9% and specificity 99.8%.<\/p>\n<p align=\"justify\">\n        <strong>Jonathan O\u2019Halloran, Chief Executive, QuantuMDx, said:<\/strong>\n      <\/p>\n<p align=\"justify\">\u201cAt the start of the outbreak, we anticipated the emergence of new strains as the pandemic progressed and designed our assay to target three different genomic regions of SARS-CoV-2.\u00a0 We can confirm that this new strain of virus will not affect our assay which maintains its high level of sensitivity in the UK and worldwide. We continue to work with regional, national, and international health authorities as we continue efforts to deliver high quality diagnostics for COVID-19. <\/p>\n<p align=\"justify\">\u201cQ-POC<sup>TM<\/sup>, our 30 min swab to result PCR point-of-care device, is nearing launch and will run an assay targeting the same three loci as the QuantuMDx SARS-CoV-2 RT-PCR Detection Assay. We are already experiencing great demand for this incredibly powerful device and want to assure our customers that our test will work across all strains represented in the online SARS-CoV-2 genome databases.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About QuantuMDx: <\/strong>\n      <\/p>\n<p>QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa \u2013 keeping it at the forefront of molecular diagnostics. For more information go to: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k5v11h4Zh5uF2mwCSywdKuTpRhARKAVw4Up03sDBgDbtgmjWtg1VR8BuyPKR5BbQyxXrX-qdjh9HiThTh4mozAEnz2gdNyCg9IqeaUDSeNQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.quantumdx.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>For media enquiries: <\/strong>\n      <\/p>\n<p align=\"justify\">Debra Daglish, Marketing Communications Manager, QuantuMDx Group, 0870 803 1234<\/p>\n<p>Chris Gardner, Matthew Neal and Lindsey Neville, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Buyrly4OxbiLDrhvZJ5vN97qi1u7Wi7MrN5Gg2kFafEAnDXBFlIPYgMS2xjhDdjwcZkwRDeIl13pJSqxM140PZRbS9muTZtzzhfatcE_dbciCY1ByY5aLOB0-pC5qXRM\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Consilium Strategic Communications<\/u><\/a>, 0203 709 5700\/ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l6dQlWtVyxFPh_nyE3f5nh2XKqYfIBAgF-1q833iwj-ejG1D8miWvDUTfH_yu7aC7AB_u9wzSnZW0PJQdzZJsOtbGjzSM2YtqiS_1_X3xcA0ugClLOQuw7aEMyp_RJky\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>quantumdx@consilium-comms.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>For investor enquiries: <\/strong>\n      <\/p>\n<p align=\"justify\">Financial Adviser: WG Partners LLP; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AkS4r999ZS3qyVkTGa_PXW2KY5MhEogkp2OOeaxZK4_AiSf_9Ocawv-GrhrCH_ax8XXhtLTzQMpAM4TvFeSjTIY-lUY285gBIofcUJK7aeI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>David Wilson<\/u><\/a> (020\u00a03705\u00a09315), <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EMEuU-uFo6zYTQQIY3KGQAA7em61XcyEYZUke4RtSdtpb_i1qBJc3pfEJuWXLqzBClcX1eUFPx-TEOoTm32YusUJprnL1mSExpuBiVoSLDI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Nigel Barnes<\/u><\/a> (020\u00a03705\u00a09318), <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4sQpBWNKSdjAc_dQr_KSLx5cv9uloc2bfpuW2kCxWu2Z9N2cK93d2a9Yhn7jckpxYpf6SPfGKg4g9Nz6tlg6EaUCQELXfvEagex1QjYDB20=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Claes Sp<\/u><u>\u00e5<\/u><u>ng<\/u><\/a> (020\u00a03705\u00a09317)<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/b62142dd-b1f0-422b-ba1b-791edb8790e8\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01 NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx Group Limited (\u201cQuantuMDx\u201d), a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new strain of SARS-CoV-2. The UK COVID Genomics Consortium and Public Health England have identified a new strain of SARS-CoV-2 which is characterised by multiple spike gene variants. The new strain known as VUI-202012\/01 or lineage B.1.1.7 appears to be significantly more transmissible than other circulating linages and there are reports that some diagnostic tests may be affected. QuantuMDx continually monitors genomic sequences &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-404268","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01 NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx Group Limited (\u201cQuantuMDx\u201d), a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new strain of SARS-CoV-2. The UK COVID Genomics Consortium and Public Health England have identified a new strain of SARS-CoV-2 which is characterised by multiple spike gene variants. The new strain known as VUI-202012\/01 or lineage B.1.1.7 appears to be significantly more transmissible than other circulating linages and there are reports that some diagnostic tests may be affected. QuantuMDx continually monitors genomic sequences &hellip; Continue reading &quot;QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-22T12:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\\\/01\",\"datePublished\":\"2020-12-22T12:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/\"},\"wordCount\":453,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/\",\"name\":\"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\\\/01 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5\",\"datePublished\":\"2020-12-22T12:03:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\\\/01\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/","og_locale":"en_US","og_type":"article","og_title":"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01 - Market Newsdesk","og_description":"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01 NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx Group Limited (\u201cQuantuMDx\u201d), a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new strain of SARS-CoV-2. The UK COVID Genomics Consortium and Public Health England have identified a new strain of SARS-CoV-2 which is characterised by multiple spike gene variants. The new strain known as VUI-202012\/01 or lineage B.1.1.7 appears to be significantly more transmissible than other circulating linages and there are reports that some diagnostic tests may be affected. QuantuMDx continually monitors genomic sequences &hellip; Continue reading \"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-22T12:03:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01","datePublished":"2020-12-22T12:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/"},"wordCount":453,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/","name":"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5","datePublished":"2020-12-22T12:03:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NzI2NCM0MDA4NDIxMDkjNzAwMDExODM5"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantumdx-diagnostic-test-for-sars-cov-2-remains-suitable-for-the-detection-of-all-discovered-variants-including-vui-202012-01\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012\/01"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=404268"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404268\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=404268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=404268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=404268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}